Collegium Pharmaceutical reports record Q3 revenue and strong ADHD growth
Collegium Pharmaceutical posted third‑quarter net product revenue of $216.3 million, a 3% year‑over‑year increase, driven primarily by its ADHD franchise. Jornay PM generated between $52 million and $59.5 million in revenue, up 24%, while Azstarys contributed $26.5 million after a modest prescription rise. The pain portfolio delivered $138 million in revenue, with BELBUCA flat at $57.7 million and Xtampza ER down 9% to $45.8 million. The company completed a $50 million accelerated share repurchase and kept $100 million of authorized buyback capacity, while reaffirming its 2026 guidance for flat adjusted EBITDA.
Why it matters
The reaffirmed guidance signals that adjusted EBITDA will remain flat for the year, limiting upside for earnings growth. Ongoing cash generation and the completed $50 million buyback give the firm flexibility to reduce debt or return capital to shareholders.
Key facts
- 1Third‑quarter net product revenue was $216.3 million, up 3% YoY. tipranks.com
- 2ADHD products represented more than 36% of total revenue. tipranks.com
- 3Jornay PM revenue was between $52 million and $59.5 million, up 24%. tipranks.com
- 4Jornay PM prescriptions increased 16% YoY. tipranks.com
- 5Azstarys generated $26.5 million in revenue with roughly 2% prescription growth. tipranks.com
- 6Pain portfolio revenue was $138 million. tipranks.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.